ClinicalTrials.gg
WithdrawnNCT01221636Updated Sep 1, 2015

Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept

A Phase 1 interventional study of Abatacept in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-01.

Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
59th of 63
0 · median 119
Started
2010
with 1 other
Phase 1
8 of 63
none open now
Registered
25th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 59th largest by enrollment, is one of 2 that started in 2010, is one of 8 in phase 1, and was the 25th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the blood levels of abatacept drug product manufactured using High Metals and using Low Metals are comparable in healthy subjects.

Read the detailed description

Compare the pharmacokinetic (PK) of High Metals abatacept relative to Low Metals abatacept following a single intravenous infusion of 750 mg in healthy subjects.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
  • Body weight will be between 60 and 100 kg, inclusive

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Any major surgery within 4 weeks of study drug administration
  • Smoking more than 10 cigarettes per day
  • Recent (within 6 months of study drug administration) drug or alcohol abuse
  • Positive blood screen for antibody, surface antigen, or -1, -2 antibody
  • History of any significant drug allergy or asthma
  • Women who are pregnant or breastfeeding and/or unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    Low Metal Abatacept

    Reference

    Drug: Abatacept

  • Experimental
    High Metal Abatacept

    Drug: Abatacept

Interventions

  • Solution for injection, Intravenous, 750 mg, 1 day

    Also known as: Orencia, BMS-188667

06

What researchers measure

Primary outcomes

  1. Single-dose pharmacokinetic parameters: Cmax (Maximum observed serum concentration)

    Time frame: Over 71 days after single dose administered

  2. Single-dose pharmacokinetic parameters: AUC 0-71 days (Area under the serum concentration-time curve from time zero to 71 days)

    Time frame: Over 71 days after single dose administered

  3. Single-dose pharmacokinetic parameters: AUC (INF) (Area under the serum concentration-time curve from time zero extrapolated to infinity)

    Time frame: Over 71 days after single dose administered

Secondary outcomes

  1. Immunogenicity determination will be based on titers of anti abatacept and anti-CTLA-4-T antibodies in serum over time

    Time frame: Days 29, 57, and 71 after single dose administered

  2. Safety assessments: adverse events, vital sign measurements, ECGs, physical examinations, and clinical laboratory tests. The incidence of observed adverse events will be tabulated and reviewed for potential significance and clinical importance

    Time frame: Days 1, 2, 4, 8, 15, 22, 29, 43, 57 and 71 after single dose administration

07

Study locations

1 site
  • Local Institution
    Austin, Texas 78744, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2010
First posted
Oct 15, 2010
Start
Oct 2010
Primary completionEst.
Feb 2011
CompletionEst.
Feb 2011
Last update
Sep 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01221636
First posted
Oct 15, 2010
Start date
Oct 2010
Primary completion
Feb 2011 (estimated)
Completion
Feb 2011 (estimated)
Last update
Sep 1, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion